MYSILDECARD

This brand name is authorized in Austria, Croatia, Estonia, France, Germany, Ireland, Italy, Lithuania, Netherlands, Poland, Romania, Spain.

Active ingredients

The drug MYSILDECARD contains one active pharmaceutical ingredient (API):

1	Sildenafil UNII BW9B0ZE037 - SILDENAFIL CITRATE
	Sildenafil is a potent and selective inhibitor of cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5), the enzyme that is responsible for degradation of cGMP. Apart from the presence of this enzyme in the corpus cavernosum of the penis, PDE5 is also present in the pulmonary vasculature. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation.
	Read more about Sildenafil

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MYSILDECARD Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G04BE03	Sildenafil	G Genito urinary system and sex hormones → G04 Urologicals → G04B Other urologicals, incl. antispasmodics → G04BE Drugs used in erectile dysfunction
Discover more medicines within G04BE03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	12457176, 12661994
EE	Ravimiamet	1729166, 1729177
ES	Centro de información online de medicamentos de la AEMPS	1161134003
FR	Base de données publique des médicaments	69190025
IE	Health Products Regulatory Authority	88036
IT	Agenzia del Farmaco	045112036
LT	Valstybinė vaistų kontrolės tarnyba	1081049, 1081050, 1081051
NL	Z-Index G-Standaard, PRK	80365
PL	Rejestru Produktów Leczniczych	100377552
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68188001